Cargando…
Immunogenicity of SARS-CoV-2 vaccination in patients undergoing autologous stem cell transplantation. A multicentric experience
COVID-19 disease has a strong impact on hematological patients; those receiving autologous hematopoietic stem cell transplantation (aHSCT) represent a particularly vulnerable group, in which the effectiveness of vaccination is very variable. Chiarucci et al. showed that patients affected by non-Hodg...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755510/ https://www.ncbi.nlm.nih.gov/pubmed/36531008 http://dx.doi.org/10.3389/fonc.2022.897937 |
_version_ | 1784851436642762752 |
---|---|
author | Autore, Francesco Stirparo, Luca Innocenti, Idanna Papa, Elena Marchesi, Francesco Togni, Chiara Mariani, Sabrina Torrieri, Lorenzo Salvatori, Martina Fazio, Francesca Metafuni, Elisabetta Giammarco, Sabrina Sora, Federica Falcucci, Paolo Ferrari, Antonella Trisolini, Silvia Maria Capria, Saveria Tafuri, Agostino Chiusolo, Patrizia Sica, Simona Laurenti, Luca |
author_facet | Autore, Francesco Stirparo, Luca Innocenti, Idanna Papa, Elena Marchesi, Francesco Togni, Chiara Mariani, Sabrina Torrieri, Lorenzo Salvatori, Martina Fazio, Francesca Metafuni, Elisabetta Giammarco, Sabrina Sora, Federica Falcucci, Paolo Ferrari, Antonella Trisolini, Silvia Maria Capria, Saveria Tafuri, Agostino Chiusolo, Patrizia Sica, Simona Laurenti, Luca |
author_sort | Autore, Francesco |
collection | PubMed |
description | COVID-19 disease has a strong impact on hematological patients; those receiving autologous hematopoietic stem cell transplantation (aHSCT) represent a particularly vulnerable group, in which the effectiveness of vaccination is very variable. Chiarucci et al. showed that patients affected by non-Hodgkin lymphoma (NHL) and treated with rituximab experienced a lower rate of immunization against SARS-CoV-2 (54%), as well as significantly lower IgG antibody titers. In our multicenter retrospective observational study, we included 82 patients who underwent aHSCT, divided into two groups: 58 patients vaccinated after aHSCT (group A) and 24 vaccinated before getting transplantation (group B). In group A, 39 (67%) patients had positive serology, and the rate of positivity increased with time after aHSCT. In the subgroup of patients with NHL, the administration of rituximab predicted negative serology, particularly when administered in the 6 months before vaccination (13% response rate). Patients affected by plasma cells had a higher rate of positivity (83% overall), independently of the time to aHSCT. In group B, no patient who initially showed positive serology became negative after transplantation, so the aHSCT did not affect the response to the vaccination. Our study confirmed the role of rituximab as a negative predictor of response to SARS-CoV-2 vaccination, whereas the conditioning and transplantation procedure itself seemed to be less important. |
format | Online Article Text |
id | pubmed-9755510 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97555102022-12-17 Immunogenicity of SARS-CoV-2 vaccination in patients undergoing autologous stem cell transplantation. A multicentric experience Autore, Francesco Stirparo, Luca Innocenti, Idanna Papa, Elena Marchesi, Francesco Togni, Chiara Mariani, Sabrina Torrieri, Lorenzo Salvatori, Martina Fazio, Francesca Metafuni, Elisabetta Giammarco, Sabrina Sora, Federica Falcucci, Paolo Ferrari, Antonella Trisolini, Silvia Maria Capria, Saveria Tafuri, Agostino Chiusolo, Patrizia Sica, Simona Laurenti, Luca Front Oncol Oncology COVID-19 disease has a strong impact on hematological patients; those receiving autologous hematopoietic stem cell transplantation (aHSCT) represent a particularly vulnerable group, in which the effectiveness of vaccination is very variable. Chiarucci et al. showed that patients affected by non-Hodgkin lymphoma (NHL) and treated with rituximab experienced a lower rate of immunization against SARS-CoV-2 (54%), as well as significantly lower IgG antibody titers. In our multicenter retrospective observational study, we included 82 patients who underwent aHSCT, divided into two groups: 58 patients vaccinated after aHSCT (group A) and 24 vaccinated before getting transplantation (group B). In group A, 39 (67%) patients had positive serology, and the rate of positivity increased with time after aHSCT. In the subgroup of patients with NHL, the administration of rituximab predicted negative serology, particularly when administered in the 6 months before vaccination (13% response rate). Patients affected by plasma cells had a higher rate of positivity (83% overall), independently of the time to aHSCT. In group B, no patient who initially showed positive serology became negative after transplantation, so the aHSCT did not affect the response to the vaccination. Our study confirmed the role of rituximab as a negative predictor of response to SARS-CoV-2 vaccination, whereas the conditioning and transplantation procedure itself seemed to be less important. Frontiers Media S.A. 2022-12-02 /pmc/articles/PMC9755510/ /pubmed/36531008 http://dx.doi.org/10.3389/fonc.2022.897937 Text en Copyright © 2022 Autore, Stirparo, Innocenti, Papa, Marchesi, Togni, Mariani, Torrieri, Salvatori, Fazio, Metafuni, Giammarco, Sora, Falcucci, Ferrari, Trisolini, Capria, Tafuri, Chiusolo, Sica and Laurenti https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Autore, Francesco Stirparo, Luca Innocenti, Idanna Papa, Elena Marchesi, Francesco Togni, Chiara Mariani, Sabrina Torrieri, Lorenzo Salvatori, Martina Fazio, Francesca Metafuni, Elisabetta Giammarco, Sabrina Sora, Federica Falcucci, Paolo Ferrari, Antonella Trisolini, Silvia Maria Capria, Saveria Tafuri, Agostino Chiusolo, Patrizia Sica, Simona Laurenti, Luca Immunogenicity of SARS-CoV-2 vaccination in patients undergoing autologous stem cell transplantation. A multicentric experience |
title | Immunogenicity of SARS-CoV-2 vaccination in patients undergoing autologous stem cell transplantation. A multicentric experience |
title_full | Immunogenicity of SARS-CoV-2 vaccination in patients undergoing autologous stem cell transplantation. A multicentric experience |
title_fullStr | Immunogenicity of SARS-CoV-2 vaccination in patients undergoing autologous stem cell transplantation. A multicentric experience |
title_full_unstemmed | Immunogenicity of SARS-CoV-2 vaccination in patients undergoing autologous stem cell transplantation. A multicentric experience |
title_short | Immunogenicity of SARS-CoV-2 vaccination in patients undergoing autologous stem cell transplantation. A multicentric experience |
title_sort | immunogenicity of sars-cov-2 vaccination in patients undergoing autologous stem cell transplantation. a multicentric experience |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755510/ https://www.ncbi.nlm.nih.gov/pubmed/36531008 http://dx.doi.org/10.3389/fonc.2022.897937 |
work_keys_str_mv | AT autorefrancesco immunogenicityofsarscov2vaccinationinpatientsundergoingautologousstemcelltransplantationamulticentricexperience AT stirparoluca immunogenicityofsarscov2vaccinationinpatientsundergoingautologousstemcelltransplantationamulticentricexperience AT innocentiidanna immunogenicityofsarscov2vaccinationinpatientsundergoingautologousstemcelltransplantationamulticentricexperience AT papaelena immunogenicityofsarscov2vaccinationinpatientsundergoingautologousstemcelltransplantationamulticentricexperience AT marchesifrancesco immunogenicityofsarscov2vaccinationinpatientsundergoingautologousstemcelltransplantationamulticentricexperience AT tognichiara immunogenicityofsarscov2vaccinationinpatientsundergoingautologousstemcelltransplantationamulticentricexperience AT marianisabrina immunogenicityofsarscov2vaccinationinpatientsundergoingautologousstemcelltransplantationamulticentricexperience AT torrierilorenzo immunogenicityofsarscov2vaccinationinpatientsundergoingautologousstemcelltransplantationamulticentricexperience AT salvatorimartina immunogenicityofsarscov2vaccinationinpatientsundergoingautologousstemcelltransplantationamulticentricexperience AT faziofrancesca immunogenicityofsarscov2vaccinationinpatientsundergoingautologousstemcelltransplantationamulticentricexperience AT metafunielisabetta immunogenicityofsarscov2vaccinationinpatientsundergoingautologousstemcelltransplantationamulticentricexperience AT giammarcosabrina immunogenicityofsarscov2vaccinationinpatientsundergoingautologousstemcelltransplantationamulticentricexperience AT sorafederica immunogenicityofsarscov2vaccinationinpatientsundergoingautologousstemcelltransplantationamulticentricexperience AT falcuccipaolo immunogenicityofsarscov2vaccinationinpatientsundergoingautologousstemcelltransplantationamulticentricexperience AT ferrariantonella immunogenicityofsarscov2vaccinationinpatientsundergoingautologousstemcelltransplantationamulticentricexperience AT trisolinisilviamaria immunogenicityofsarscov2vaccinationinpatientsundergoingautologousstemcelltransplantationamulticentricexperience AT capriasaveria immunogenicityofsarscov2vaccinationinpatientsundergoingautologousstemcelltransplantationamulticentricexperience AT tafuriagostino immunogenicityofsarscov2vaccinationinpatientsundergoingautologousstemcelltransplantationamulticentricexperience AT chiusolopatrizia immunogenicityofsarscov2vaccinationinpatientsundergoingautologousstemcelltransplantationamulticentricexperience AT sicasimona immunogenicityofsarscov2vaccinationinpatientsundergoingautologousstemcelltransplantationamulticentricexperience AT laurentiluca immunogenicityofsarscov2vaccinationinpatientsundergoingautologousstemcelltransplantationamulticentricexperience |